With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.